Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
Cancer Drug Shortages Result in Almost no Treatment Changes, USC Study Finds
Jacobson and Alpert studied more than 2.4 million monthly claims for chemotherapy treatment and found little impact on outpatient chemotherapy treatment for the majority of oncology drugs identified as experiencing shortages between 2004 and 2011.
-
A Conversation with Departing FDA Commissioner Scott Gottlieb on his Tenure and Policy Reforms
USC-Brookings Schaeffer Initiative for Health Policy, in partnership with the Hutchins Center on Fiscal & Monetary Policy, is co-hosting a conversation with outgoing FDA Commissioner Scott Gottlieb.
-
World Class: A Conversation with Author Dr. William A. Haseltine
The USC-Brookings Schaeffer Initiative for Health Policy will host Dr. William A. Haseltine for a discussion on his latest book, “World Class: A Story of Adversity, Transformation, and Success at NYU Langone Health.”
-
Joint Recommendations of USC-Brookings Schaeffer Initiative for Health Policy and AEI Scholars to Reduce Healthcare Costs
The experts recommendations to the Senate committee aimed at four main goals: improving incentives in private insurance, removing state regulatory barriers to provider market competition, improving incentives in the Medicare program, and promoting competition in the pharmaceutical market.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Ending Drug Rebates will Increase Medicare Part D Premiums, but Most Seniors will be Insulated From It
Erin Trish and Dana Goldman argue eliminating drug rebates will increase the cost of Medicare Part D premiums, but most seniors will be not feel the effects. They say seniors should ignore pharmacy benefit managers’ alarm raised by the proposal.
Categorized in -
The U.S. Should Assess the Economic Value of Drugs Rather Than Leave it up to Other Countries
Why are prescription drugs are often priced lower overseas? Many countries perform detailed assessments of the economic value of drugs and their benefits, and this could work in the U.S., says William Padula
Categorized in -
A New Model for Pricing Drugs of Uncertain Efficacy
Goldman, Van Nuys and colleagues propose a three-part pricing (TPP) model that ties prices to value but removes the need to monitor efficacy in each patient. The model creates a tiered system, with prices varying over fixed time intervals.
Categorized in -
Mortality Risk, Insurance, and the Value of Life
People with shorter life expectancies place more value on increases in survival than people who anticipate longer life spans.
Categorized in -
The Bigger Message Behind Amgen’s Decision to Slash Cost of its Repatha Cholesterol Drug
Drug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealth writes Goldman in MarketWatch.
Categorized in -
White House Signs Bills Banning Gag Clauses, Schaeffer Center Research Pivotal in Discussion
Schaeffer Center report found 23 percent of private claims analyzed involved a copayment that exceeded the insurer’s cost of the drug.